dm+d
Unassigned
New Medicines
Moderate to severe atopic dermatitis, inadequately controlled by other therapies
Information
New molecular entity
Galderma
Galderma
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
A humanised monoclonal antibody targeted against the IL-31 receptor, a cytokine reported to be associated with pruritus in atopic dermatitis [1]
Atopic eczema is common and the prevalence is increasing. Eczema affects 15-20% of school children and 2-10% of adults.
Moderate to severe atopic dermatitis, inadequately controlled by other therapies
Subcutaneous
Moderate to severe prurigo nodularis (PN)
Information
Licence extension / variation
Galderma
Galderma
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
A humanised monoclonal antibody targeted against the IL-31 receptor, a cytokine reported to be associated with pruritus in atopic dermatitis
The condition appears to be relatively common, particularly among patients who have some of the associated/precipitating conditions (infections, acute kidney injury, psychiatric conditions, malignancies); however, there are no surveys of its prevalence in the general population. It is more common in middle-aged women [1].
Moderate to severe prurigo nodularis (PN)
Subcutaneous injection